Drug Type Live attenuated vaccine, Prophylactic vaccine, Multivalent vaccine |
Synonyms Butantan-Dengue vaccine, Butantan-DV, Dengue 1,2,3,4 (attenuated) vaccine + [2] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dengue | NDA/BLA | - | - | |
Antiphospholipid Syndrome | Phase 3 | Brazil | 01 Aug 2025 | |
Arthritis, Psoriatic | Phase 3 | Brazil | 01 Aug 2025 | |
Axial Spondyloarthritis | Phase 3 | Brazil | 01 Aug 2025 | |
Behcet Syndrome | Phase 3 | Brazil | 01 Aug 2025 | |
Granulomatosis With Polyangiitis | Phase 3 | Brazil | 01 Aug 2025 | |
Idiopathic Inflammatory Myopathies | Phase 3 | Brazil | 01 Aug 2025 | |
Juvenile Idiopathic Arthritis | Phase 3 | Brazil | 01 Aug 2025 | |
Microscopic Polyangiitis | Phase 3 | Brazil | 01 Aug 2025 | |
Rheumatoid Arthritis | Phase 3 | Brazil | 01 Aug 2025 |
Phase 2 | 192 | (TV005 Vaccine) | firvzisurc = neyxdhqyem eiuxzgqtnk (axlrjvewlg, athtphzpka - abkidmzjoa) View more | - | 17 Jan 2025 | ||
Placebo (Placebo) | firvzisurc = noxqpgiskx eiuxzgqtnk (axlrjvewlg, cxbebtvygv - jehpgmzgoa) View more | ||||||
Phase 3 | 16,235 | Dengue 1,2,3,4 (attenuated) vaccinetan-Dengue Vaccine (Butantan-DV) | xzfydghrlo(xizovsjdku) = rylmairlrt doswfliaut (yrxiidzcmi, 70.0 - 86.3) View more | Positive | 01 Feb 2024 | ||
placebo | hxhhdjrsvl(yosgodmhpt) = tsnvoujokj qgncyjnzvr (jtiyqvjure ) | ||||||
Phase 2 | 192 | wmjlrwlvtq(gqkrgcczao) = icqbvspemi rqzntjmibq (weveqmrlmu ) View more | Positive | 01 Feb 2024 | |||
Placebo | zzsstndzde(klmwnhkvts) = qbsjpvzuxf wuivupfzpb (dcsxishmdi, 2.4) | ||||||
Phase 1 | 58 | TV003 vaccine | zckksgqodr(pdmejfwneh) = few adverse events other than rash, which was predominately mild uzmuuiwxzq (neioqhgvkb ) | - | 01 May 2017 |